Ghent/Cambridge, Ma, 22 April 2021 – On Thursday 15 April 2021, Valerie Morel became the new CEO of ONTOFORCE, the developer of life sciences data management applications. Morel is a seasoned executive with 20 years of management and board experience in life sciences, financial services, data, and technology. She holds a degree as a Commercial Engineer (KULeuven, 1991).
ONTOFORCE to accelerate growth and scale up globally under new CEO’s leadership
“ONTOFORCE has built a great product, and the market is ready for it – especially as the COVID-19 pandemic further accelerated the demand for integrated and structured data in life sciences,” says Morel.
As CEO, Valerie Morel will build on ONTOFORCE’s mature product and scale it up globally. Since its establishment in 2011, ONTOFORCE has addressed a major challenge for life sciences companies: bringing together structured and unstructured data to create new insights. These insights lead to accelerated drug discovery, optimized clinical trial research, and a faster go-to-market.
ONTOFORCE works with a wide range of life sciences companies, including Amgen, UCB, and Roche. In addition, the company also collaborates closely with renowned international research institutions such as IMEC, UGent, and KULeuven.
Valerie Morel, CEO of ONTOFORCE: “I’m excited to be joining ONTOFORCE and to lead it through its next growth phase. ONTOFORCE has built a great product, and the market is ready for it – especially as the COVID-19 pandemic further accelerated the demand for reliable and structured data in life sciences. The convenience and data management power of ONTOFORCE’s product makes it the perfect answer to a growing need. I am looking forward to working together with the team to achieve great things as we take ONTOFORCE global.”
‘Save lives thanks to smarter data use’
At ONTOFORCE, Morel joins forces once more with its chairman, Hans Cobben, with whom she worked at Bluebee, the Netherlands-based genomics cloud data developer recently acquired by Illumina.
“Valerie’s track record of growing global technology companies makes her the perfect match for ONTOFORCE. The digitalization of life sciences has accelerated significantly over the past year. This data deluge requires reliable and convenient tools like ours to aggregate and explore data and generate new insights. Ultimately, ONTOFORCE will be a driver for exciting new possibilities in personalized medicine, drug discovery, and biomarker discovery,” adds Hans Cobben, chairman of ONTOFORCE.
“Ten years ago, we founded ONTOFORCE with the vision that using more and smarter data in drug discovery and development can save lives. Today, the life sciences industry is ready to adopt our vision wholeheartedly, and ONTOFORCE is ready to deliver on that big promise. As we enter this exciting new phase with the company, I have decided that it is a great moment to step back from my operational tasks in the company. I am very proud of where we are and I am absolutely confident that Valerie is the right person to guide this company towards global expansion,” concludes Hans Constandt, founder of ONTOFORCE.
For more than a decade, ONTOFORCE has addressed the problem that many life sciences companies struggle with when bringing together structured and unstructured data to create new insights. These insights lead to accelerated drug discovery, more in-depth insights into research, real-world evidence, optimized clinical trial research, and a faster go-to-market.
ONTOFORCE already works for lighthouse customers such as Amgen, UCB, BMS, Roche, Medidata, and numerous other life sciences colleagues. Thanks to the intense collaboration with renowned research institutes such as IMEC, VIB, UGent, KULeuven, and international research and industrial consortia such as ELIXIR, FAIRplus, and Pistoia Alliance, it guarantees that you are engaging with a global player that has made transforming data into insights its primary objective.